|
Class 2 Device Recall Bond Elut Dried Matrix Spotting (DMS) cards |
 |
Date Initiated by Firm |
June 17, 2015 |
Create Date |
April 05, 2017 |
Recall Status1 |
Terminated 3 on April 05, 2017 |
Recall Number |
Z-1737-2017 |
Recall Event ID |
76698 |
Product Classification |
Newborn screening specimen collection paper - Product Code PJC
|
Product |
Bond Elut OMS (Dried Matrix Spotting)' Product;
Catalog model numbers: 5022-8226 - Auto DBS Card (LCMS Extraction Sys) 50 pk; A400150 - Bond Elut EMS Card 50/Pk; A400150K - Bond Elut DMS Card BULK 500/pk; A400150SK - Bond Elut DMS Card Starter Kit A42001 - Bond Elut MDS Card Accessory Pack
Product Usage: For use in the analysis of dried blood spots and other biological matrices in research applications for drug metabolism pharmacokinetics/ absorption, distribution. metabolism and excretion (DMPK/ ADME) studies. |
Code Information |
All |
Recalling Firm/ Manufacturer |
Agilent Technologies, Inc. 5301 Stevens Creek Blvd Santa Clara CA 95051-7201
|
For Additional Information Contact |
Rose Romeo 408-345-8214
|
Manufacturer Reason for Recall |
The product was marketed without 510(k) clearance.
|
FDA Determined Cause 2 |
No Marketing Application |
Action |
Agilent Technologies Letters via e-mail were sent to customers on June 17, 2015.
Letters advised that the Bond Elut DMS Product was being withdrawn from the market. |
Quantity in Commerce |
364 in total |
Distribution |
US and Australia, Thailand, Great Britain, Germany, Japan, Netherlands, France, Taiwan, Canada, South Africa, China, Slovenia, Spain, Italy, Norway, India, Russia, Finland, Czech Republic, Singapore, Denmark, Korea, Ireland, United Arab Emirates, .Belgium, Switzerland and Sweden. |
Total Product Life Cycle |
TPLC Device Report
|
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
|
|
|